Novartis announced positive topline results from the Phase III REACH2 study evaluating Jakavi (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Administratorhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAdministrator2019-10-16 07:00:352019-10-16 13:15:10Novartis’ Jakavi meets primary endpoint in Phase III study of acute graft-versus-host disease
